TW201823235A - 西克里維羅（ｃｅｎｉｃｒｉｖｉｒｏｃ）甲磺酸鹽之固體型式和製造西克里維羅甲磺酸鹽之固體型式的方法 - Google Patents
西克里維羅（ｃｅｎｉｃｒｉｖｉｒｏｃ）甲磺酸鹽之固體型式和製造西克里維羅甲磺酸鹽之固體型式的方法 Download PDFInfo
- Publication number
- TW201823235A TW201823235A TW106129555A TW106129555A TW201823235A TW 201823235 A TW201823235 A TW 201823235A TW 106129555 A TW106129555 A TW 106129555A TW 106129555 A TW106129555 A TW 106129555A TW 201823235 A TW201823235 A TW 201823235A
- Authority
- TW
- Taiwan
- Prior art keywords
- crystalline form
- msoh
- compound
- patent application
- scope
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662382153P | 2016-08-31 | 2016-08-31 | |
| US62/382,153 | 2016-08-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW201823235A true TW201823235A (zh) | 2018-07-01 |
Family
ID=61241572
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW106129555A TW201823235A (zh) | 2016-08-31 | 2017-08-30 | 西克里維羅（ｃｅｎｉｃｒｉｖｉｒｏｃ）甲磺酸鹽之固體型式和製造西克里維羅甲磺酸鹽之固體型式的方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10301287B2 (enExample) |
| EP (1) | EP3506896A4 (enExample) |
| JP (2) | JP2019526628A (enExample) |
| KR (1) | KR20190057066A (enExample) |
| CN (1) | CN110167550A (enExample) |
| AU (1) | AU2017321594A1 (enExample) |
| BR (1) | BR112019003987A2 (enExample) |
| CA (1) | CA3034606A1 (enExample) |
| MX (1) | MX2019002057A (enExample) |
| RU (1) | RU2019109019A (enExample) |
| SG (1) | SG11201901438VA (enExample) |
| TW (1) | TW201823235A (enExample) |
| WO (1) | WO2018045043A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019238041A1 (zh) * | 2018-06-12 | 2019-12-19 | 南京明德新药研发有限公司 | 一种丙烯酰胺类化合物的晶型及其制备方法 |
| WO2019245518A1 (en) * | 2018-06-18 | 2019-12-26 | Hewlett-Packard Development Company, L.P. | Three-dimensional printing |
| WO2019245517A1 (en) * | 2018-06-18 | 2019-12-26 | Hewlett-Packard Development Company, L.P. | Three-dimensional printing |
| US11426931B2 (en) | 2018-06-19 | 2022-08-30 | Hewlett-Packard Development Company, L.P. | Three-dimensional printing |
| WO2019245535A1 (en) | 2018-06-19 | 2019-12-26 | Hewlett-Packard Development Company, L.P. | Three-dimensional printing |
| US11298876B2 (en) | 2018-06-19 | 2022-04-12 | Hewlett-Packard Development Company, L.P. | Three-dimensional printing |
| EP3844209B1 (en) * | 2018-08-31 | 2022-06-22 | Evonik Operations GmbH | Process for preparing a polymer powder |
| WO2021133811A1 (en) | 2019-12-26 | 2021-07-01 | Teva Pharmaceuticals International Gmbh | Solid state forms of cenicriviroc and process for preparation thereof |
| WO2021233349A1 (zh) | 2020-05-22 | 2021-11-25 | 南京明德新药研发有限公司 | 吡啶类衍生物及其应用 |
| WO2022177014A1 (ja) * | 2021-02-22 | 2022-08-25 | 旭化成株式会社 | セルロースナノファイバーを含む組成物 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS62265270A (ja) | 1986-05-13 | 1987-11-18 | Zeria Shinyaku Kogyo Kk | 新規イミダゾ−ル誘導体およびそれらを有効成分とする抗潰瘍剤 |
| DE69520360T2 (de) | 1994-07-04 | 2001-08-09 | Takeda Chemical Industries, Ltd. | Phosphonsäure verbindungen imre herstellung und verwendung |
| CN1282243A (zh) | 1997-12-19 | 2001-01-31 | 武田药品工业株式会社 | 用于拮抗ccr5的含n－酰苯胺衍生物的药物组合物 |
| AU5301599A (en) | 1998-08-20 | 2000-03-14 | Takeda Chemical Industries Ltd. | Quaternary ammonium salts and their use |
| WO2001017947A1 (en) | 1999-09-06 | 2001-03-15 | Takeda Chemical Industries, Ltd. | Process for the preparation of 2,3-dihydroazepine compounds |
| DE60235632D1 (de) | 2001-08-08 | 2010-04-22 | Tobira Therapeutics Inc | Bicyclische verbindung, deren herstellung und verwendung |
| EP1484322A4 (en) | 2002-03-12 | 2008-01-23 | Takeda Pharmaceutical | PROCESS FOR PRODUCING AN OPTICALLY ACTIVE SULFOXIDE DERIVATIVE |
| US20080249147A1 (en) | 2004-03-24 | 2008-10-09 | Takeda Pharmaceutical Company Limited | Emulsion-Stabilized Preparation |
| JP2007269628A (ja) * | 2004-05-28 | 2007-10-18 | Takeda Chem Ind Ltd | 医薬化合物の結晶 |
| GT200600148A (es) | 2005-04-14 | 2006-11-22 | Metodos para el tratamiento y la prevencion de fibrosis | |
| PE20140406A1 (es) | 2010-11-18 | 2014-04-16 | Univ Yale | Moleculas bifuncionales con actividad de reclutamiento de anticuerpos y actividad inhibitoria inicial contra el virus de la inmunodeficiencia humana |
| EP2846788A1 (en) * | 2012-05-11 | 2015-03-18 | Akron Molecules AG | Use of compounds for the treatment of pain |
| UA115807C2 (uk) | 2013-05-15 | 2017-12-26 | Тобіра Терап'Ютикс, Інк. | Композиція (варіанти) ценікривіроку і спосіб її одержання та застосування (варіанти) |
| RU2020119611A (ru) | 2014-03-21 | 2020-06-29 | Тобира Терапьютикс, Инк. | Сенекривирок для лечения фиброза |
| US20170105969A1 (en) | 2014-06-02 | 2017-04-20 | Tobira Therapeutics, Inc. | Cenicriviroc for the treatment of hiv-2 infection |
| CN112266392A (zh) * | 2014-12-23 | 2021-01-26 | 妥必徕疗治公司 | 制备cenicriviroc及相关类似物的方法 |
-
2017
- 2017-08-30 RU RU2019109019A patent/RU2019109019A/ru not_active Application Discontinuation
- 2017-08-30 JP JP2019531594A patent/JP2019526628A/ja active Pending
- 2017-08-30 CA CA3034606A patent/CA3034606A1/en not_active Abandoned
- 2017-08-30 AU AU2017321594A patent/AU2017321594A1/en not_active Abandoned
- 2017-08-30 WO PCT/US2017/049400 patent/WO2018045043A1/en not_active Ceased
- 2017-08-30 MX MX2019002057A patent/MX2019002057A/es unknown
- 2017-08-30 EP EP17847477.1A patent/EP3506896A4/en not_active Withdrawn
- 2017-08-30 CN CN201780061529.6A patent/CN110167550A/zh active Pending
- 2017-08-30 KR KR1020197008786A patent/KR20190057066A/ko not_active Withdrawn
- 2017-08-30 TW TW106129555A patent/TW201823235A/zh unknown
- 2017-08-30 SG SG11201901438VA patent/SG11201901438VA/en unknown
- 2017-08-30 BR BR112019003987A patent/BR112019003987A2/pt not_active Application Discontinuation
- 2017-08-30 US US15/691,191 patent/US10301287B2/en active Active
-
2022
- 2022-07-14 JP JP2022113230A patent/JP2022137223A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112019003987A2 (pt) | 2019-05-28 |
| MX2019002057A (es) | 2019-11-18 |
| US20180057481A1 (en) | 2018-03-01 |
| CN110167550A (zh) | 2019-08-23 |
| RU2019109019A (ru) | 2020-10-01 |
| AU2017321594A1 (en) | 2019-04-18 |
| JP2019526628A (ja) | 2019-09-19 |
| RU2019109019A3 (enExample) | 2021-08-23 |
| JP2022137223A (ja) | 2022-09-21 |
| EP3506896A4 (en) | 2020-08-26 |
| SG11201901438VA (en) | 2019-03-28 |
| WO2018045043A1 (en) | 2018-03-08 |
| US10301287B2 (en) | 2019-05-28 |
| KR20190057066A (ko) | 2019-05-27 |
| CA3034606A1 (en) | 2018-03-08 |
| EP3506896A1 (en) | 2019-07-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW201823235A (zh) | 西克里維羅（ｃｅｎｉｃｒｉｖｉｒｏｃ）甲磺酸鹽之固體型式和製造西克里維羅甲磺酸鹽之固體型式的方法 | |
| JP6081763B2 (ja) | ダサチニブ多形体およびその調製プロセス | |
| US11149017B2 (en) | Solid state forms of apalutamide | |
| EA034409B1 (ru) | Способы получения кристаллического фенилацетата l-орнитина | |
| RU2704795C2 (ru) | Кристаллическая форма бисульфата ингибитора jak и способ ее получения | |
| WO2011095059A1 (zh) | 达沙替尼多晶型物及其制备方法和药物组合物 | |
| US12209073B2 (en) | Polymorphs of a dihydroorotate dehydrogenase (DHOD) inhibitor | |
| WO2021143841A1 (zh) | 三并环类pde3/pde4双重抑制剂化合物的药物组合物 | |
| EP4486458A1 (en) | Crystalline forms of trilaciclib and trilaciclib salts | |
| US9181256B2 (en) | Salts of sitagliptin, process for the preparation and pharmaceutical composition therefore | |
| KR20190029601A (ko) | 고체 형태의 ttk 억제제 | |
| US7655800B2 (en) | Crystalline 1H-imidazo[4,5-b]pyridin-5-amine, 7-[5-[(cyclohexylmethylamino)-methyl]-1H-indol-2-yl]-2-methyl, sulfate (1:1), trihydrate and its pharmaceutical uses | |
| EP4477652A1 (en) | Polymorph as thyroid hormone receptor agonists and use thereof | |
| TW202434600A (zh) | 磺醯胺衍生物結晶形式及其製備方法 | |
| WO2019086008A1 (zh) | 一种苯并三氮唑衍生物的晶型及其制备方法和用途 | |
| WO2024179558A1 (zh) | Pirtobrutinib的晶型及其制备方法和用途 | |
| TW202543633A (zh) | 喹唑啉酮衍生物的晶型及其製備方法和應用 | |
| WO2025002335A1 (zh) | Baxdrostat的晶型及其制备方法和用途 | |
| TW202333694A (zh) | 稠環衍生物的晶型、其製備方法及其應用 | |
| KR20240063930A (ko) | 3-{[5-(아제티딘-1-일카르보닐)피라진-2-일]옥시}-5-{[(1s)-1-메틸-2-(메틸옥시)에틸]옥시)-n-(5-메틸피라진-2-일)벤즈아미드의치료 공결정 | |
| TW202304913A (zh) | １－（８－溴吡啶并［２，３－ｅ］［１，２，４］三唑并［４，３－ａ］吡𠯤－４－基）－ｎ－甲基氮雜環丁－３－胺硫酸氫鹽單水合物之新穎結晶型 | |
| WO2009007853A2 (en) | Novel polymorphs of darifenacin free base and its hydrobromide salt | |
| CN117980295A (zh) | 一种依洛西巴特晶型ii及其制备方法 | |
| CN103476753A (zh) | 新的瑞巴派特复合物和共晶体 | |
| WO2019233328A1 (zh) | 4-苯基噻唑衍生物的晶型及其制备方法 |